What is Icon's latest dividend and current dividend yield?

What guidance did Icon's management provide for the next earnings period?

What does Icon do and what are its main business segments?

What factors drove the changes in Icon's revenue and profit?

Did Icon beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Icon year over year?

What is the market's earnings forecast for Icon next quarter?

What were the key takeaways from Icon's earnings call?

- **Revenue Resilience**: Q3 $2.04B (+0.6% YoY) reflects strong RFP flow and $3B gross bookings, despite $900M cancellations. 
- **Margin Challenges**: 19.4% EBITDA margin down 20 bps QoQ due to pass-through mix, but $334M free cash flow supports $750M buybacks. 
- **2026 Outlook**: Cancellations expected to moderate, with biotech RFP growth (+20% YTD) driving direct fee wins. 
- **Tech Differentiation**: AI/automation initiatives (Orbis, risk-based quality) targeting 8%+ burn rate and cost efficiency. 
- **Share Buybacks**: $750M YTD repurchases highlight financial discipline and confidence in long-term growth.

**【CEO Summary Section】**
- ICON reported Q3 revenue of $2.043 billion, up 0.6% year-over-year and 1.3% sequentially, driven by strong RFP flow and gross bookings of $3 billion (mid-single-digit growth YoY). 
- Adjusted EBITDA was $396.7 million (19.4% margin), down 20 bps QoQ due to higher pass-through revenue mix. 
- Burn rate remained stable at 8.2%, with $334 million in free cash flow and $750 million in share buybacks YTD. 
- Full year guidance updated to $8.05-8.1 billion revenue and $13-13.20 EPS, reflecting elevated cancellations ($900 million Q3) and normalized enrollment trends. 
- Key priorities: accelerate biotech RFP conversion, optimize cost structure, and deploy AI/automation to improve efficiency.

**【CFO Financial Commentary】**
- GAAP net income was $2.4 million vs $236 million prior year, while adjusted net income was $258.8 million (16.5% tax rate). 
- Adjusted EBITDA margin of 19.4% reflected $179 million in SG&A (8.8% of revenue) and strong cost control despite $900 million in cancellations. 
- Free cash flow of $334 million Q3 ($687 million YTD) supported $250 million in share buybacks, bringing total repurchases to $750 million. 
- Leverage ratio of 1.8x net debt to EBITDA reflects strong balance sheet and flexibility for strategic investments.

**【Q&A Highlights】**
- **Cancellation Trends**: Q3 cancellations ($900 million) were in line with expectations, with bias toward pre-enrollment studies. Management expects moderation in 2026 as market normalizes post-COVID funding volatility. 
- **Gross Margin Dynamics**: Pass-through revenue mix (e.g., cardiometabolic trials) weighed on margins, but direct fee wins (+mid-single digits YoY) provide offset. 
- **Pricing Environment**: Competitive pressure in pharma is balanced by biotech RFP growth (+20% YTD). ICON focuses on winning through differentiation, not discounting. 
- **AI & Automation**: Orbis multi-agent system and risk-based quality management tools are reducing costs and improving predictability. 
- **Backlog Quality**: 2026 outlook assumes stable cancellations, with 80% of backlog in active enrollment. 
- **COVID Trials**: BARDA-related revenue now <1% of total, with no material impact on 2026 guidance.

ICON Public Limited Company (ICLR) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Q2 revenue up 1% sequentially to $2.017B, despite 4.8% YoY decline, driven by 11% sequential growth in gross business awards.
- **Margin Expansion**: Gross margin improved to 28.3%, adjusted EBITDA margin up 10bps to 19.6%, with SG&A down $9M YoY.
- **AI Innovation**: Protocol digitization reduces start-up times by 30%, showcasing ICON's efficiency gains.
- **Share Buybacks**: $250M repurchased in Q2, with $1B authorization for 2025, signaling confidence.
- **Cancellations Risk**: $916M in Q2 cancellations (including $300M COVID trial), elevated levels expected to persist.
- **China Expansion**: 3% of revenue, long-term opportunity in global trials for Chinese biotechs.

**【CEO Summary Section】**
- Q2 revenue of $2.017 billion, down 4.8% YoY but up 1% sequentially, driven by higher pass-through revenue and 11% sequential growth in gross business awards.
- Gross margin improved to 28.3% (Q1: 27.3%), with SG&A costs down $9 million YoY.
- Adjusted EBITDA of $396 million (+$5.4 million sequentially), margin up 10bps to 19.6%.
- AI initiatives, such as protocol digitization, reduced study start-up times by 30%.
- Share buybacks of $250 million in Q2, with $1 billion authorization for 2025.
- Full-year revenue guidance updated to $7.85-$8.15 billion (midpoint $8.0 billion), reflecting higher pass-through revenue.

**【CFO Financial Commentary】**
- U.S. GAAP net income of $183 million (+30.7% YoY), EPS of $2.30 vs. $1.76 prior year.
- Free cash flow of $113.9 million, cash collections solid despite timing of tax payments.
- Net debt of $3.0 billion, leverage ratio 1.9x, stable financial position.
- Adjusted EPS of $3.26 (+2.2% sequentially), despite 13.1% YoY decline.

**【Q&A Highlights】**
- **Market Segments**: Biotech bookings improved 10% sequentially, 3 of top 4 wins in biotech; pharma partnerships expanded (e.g., $300M+ awards with acquired biotechs).
- **Cancellations**: $916 million in Q2 (including $300M COVID trial), elevated cancellations expected to persist due to portfolio rationalization and negative trial results.
- **Pass-Through Revenue**: 1% of backlog, driving higher top-line but no margin; 8.2% burn rate stable through 2025.
- **Pricing Environment**: Intensified competition, but ICON maintains margin via cost controls and AI-driven efficiency.
- **China Growth**: 3% of revenue, long-term opportunity in global trials for Chinese biotechs.


ICON Public Limited Company (ICLR) Q2 2025 Earnings Call Transcript

- **Q1 Financial Resilience**: $2.0B revenue (-4.3% YoY) with 19.5% EBITDA margin, despite headwinds from cancellations and delayed trials.
- **AI Innovation**: Launch of iSubmit and SmartDraft tools to enhance operational efficiency and customer delivery.
- **Shareholder Returns**: $250M buybacks in Q1, with plans for further repurchases and strategic acquisitions.
- **Elevated Risks**: Q2 expected to see $300M cancellation impact, with ongoing uncertainty in biotech and large pharma markets.

**CEO Summary Section**
- Market dynamics: Cautious optimism amid elevated cancellations and delayed trial starts, with biotech funding challenges and mixed large pharma demand.
- Strategic initiatives: Momentum from recent partnerships, AI tool launches (iSubmit, SmartDraft), and cost alignment with demand.
- Operational focus: Standardizing processes, cross-selling lab services, and leveraging digital innovation to improve cycle times.
- Capital deployment: $250M share buybacks in Q1, with plans for further repurchases and strategic M&A.

**CFO Financial Commentary**
- Q1 Revenue: $2.0B (-4.3% YoY), impacted by delayed COVID vaccine trials.
- Adjusted EBITDA: $390.7M (19.5% margin), down 12.1% YoY due to lower gross margin (28.2% vs 29.9%).
- Adjusted EPS: $3.19 (-8.1% YoY), driven by higher R&D expenses.
- Cash flow: $268.2M from operations, $239.3M free cash flow.
- Balance sheet: $526.7M cash, $3.4B debt, 1.7x net debt/EBITDA.

**Q&A Key Takeaways**
- Cancellations: Q2 expected to see $300M impact from a large pharma study, with elevated levels likely to persist.
- Biotech trends: Increased RFPs but lower conversion rates, with cautious customer behavior.
- Large pharma: Mixed demand due to LOE pressures, but opportunities in M&A and new drug development.
- Burn rate: 8.1% in Q1, expected to remain stable with focus on accelerating trial execution.
- Guidance: Full-year revenue adjusted to reflect $350M removal of COVID trials and elevated cancellations.

ICON Public Limited Company (ICLR) Q1 2025 Earnings Call Transcript

- **Revenue resilience**: Full year +2% growth to $8.28B despite Q4 decline.
- **Backlog strength**: $24.7B (+8.3% YoY) with 8.4% Q4 burn rate.
- **Digital innovation impact**: 10% faster site activation, 24% trials on time.
- **2025 guidance**: Wide range reflects cautious biotech environment.
- **Cash flow strength**: $1.1B free cash flow, $500M buybacks in 2024.
- **Margin outlook**: 2025 EBITDA margin ~20% vs 21% in 2024.

**【CEO Summary Section】**
- ICON reported full year 2024 revenue of $8.28 billion, up 2% year-over-year, with Q4 revenue of $2.04 billion (-1.2% YoY). 
- Gross bookings in Q4 reached $3.06 billion (+8% QoQ, +3% YoY), but net book-to-bill was 1.18x due to $651 million in cancellations.
- Backlog grew to $24.7 billion (+1.4% QoQ, +8.3% YoY), with burn rate of 8.4% in Q4.
- Key wins included a Phase III full service award in cardiometabolic disease and strategic partnerships in midsize biotech.
- Digital innovation initiatives delivered 10% faster site activation, 33% fewer non-recruiting sites, and 24% trials completed on time.
- 2025 guidance reaffirmed with wide range due to cautious market environment.

**【CFO Financial Commentary】**
- Q4 GAAP net income: $260 million (+21.5% YoY), Non-GAAP EPS: $3.43 (-0.9% YoY).
- Full year 2024 free cash flow: $1.1 billion (+10% YoY), with $500 million in share buybacks.
- 2025 EBITDA margin expected to be ~1% lower than 2024 due to pass-through revenue mix in H1.
- Debt: $3.4 billion (1.7x leverage ratio), with $1 billion share repurchase authorization.

**【Q&A Highlights】**
- **Demand Environment**: Biotech bookings up low single digits, but slow trial starts. Large pharma mixed with some budget constraints.
- **Profitability**: 2025 EBITDA margin ~20% vs 21% in 2024, with H1 pressure from pass-through revenue.
- **Cost Management**: 2024 SG&A as % of revenue: 8.8% (vs 9% in 2023). 2025 automation initiatives to save $100M+ annually.
- **COVID Contracts**: ~$100M in backlog, one trial delayed but no funding issues.
- **FSP/FSO Mix**: No material change in business composition, FSP burn rate 8-9%.

Actual											1.7	1.2	1.72	1.9	2.06	2.12	2.55	2.63	2.76	2.86	3	3.13	2.9	3.11	3.3	3.46	3.47	3.75	3.35	3.43	3.19	3.26	3.31
Forecast											1.682	1.097	1.523	1.8338	1.9704	2.1327	2.3872	2.6213	2.6901	2.8084	2.9432	3.0652	2.8753	3.0759	3.2734	3.4594	3.4112	3.6822	3.8507	3.4285	3.1052	3.1884	3.3007	3.2171
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1.07%	+9.39%	+12.93%	+3.61%	+4.55%	-0.60%	+6.82%	+0.33%	+2.60%	+1.84%	+1.93%	+2.11%	+0.86%	+1.11%	+0.81%	+0.02%	+1.72%	+1.84%	-13.00%	+0.04%	+2.73%	+2.25%	+0.28%	0.00%

ICLR

ICLR fundamentals

ICLR Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

ICLR

ICLR fundamentals

ICLR Q4 2025 Earnings Preview

Earnings Call

ICLR Earnings Call Summary for Q4/2025Upcoming Apr 1, 2026

ICLR Earnings Call Summary for Q3/20258:00 AM on Oct 23, 2025

ICLR Earnings Call Summary for Q2/20258:00 AM on Jul 24, 2025

ICLR Earnings Call Summary for Q1/20258:00 AM on May 1, 2025

ICLR Earnings Call Summary for Q4/20248:00 AM on Feb 20, 2025

You can ask Aime